Overview
Huan-chang Liang practices practicing medicine in Vienna, Austria.
Liang is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses Anaplastic Large Cell Lymphoma, T-Cell Lymphoma, and Non-Hodgkin Lymphoma.
They are actively involved in clinical research, co-authoring 9 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Huan-chang Liang
Is Huan-chang Liang a top-rated expert for Anaplastic Large Cell Lymphoma?
MediFind is an objective health platform that identifies experts based on real-world data. Huan-chang Liang is classified as an Advanced expert for Anaplastic Large Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Huan-chang Liang participate in research or clinical trials?
Yes. Huan-chang Liang has published 9 articles and abstracts on conditions like Anaplastic Large Cell Lymphoma. You can view a list of Huan-chang Liang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Anaplastic Large Cell Lymphoma
- T-Cell LymphomaLiang isAdvanced. Learn about T-Cell Lymphoma.
- Experienced
- Non-Hodgkin LymphomaLiang isExperienced. Learn about Non-Hodgkin Lymphoma.